Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 3/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GSTA1 | P08263 | 5/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 5/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5574629 | 0.88 | ALDH1A1 (0.47) | CD69PGRGSTA1GSTP1TDP2 | |
| SCHEMBL16545618 | 0.75 | CD69 (0.56) | CD69PTGDR2SMN1; SMN2ELANE | |
| SCHEMBL19570312 | 0.74 | CD69 (1.00) | CD69TDP1SMN1; SMN2ELANE | |
| SCHEMBL18538268 | 0.74 | CD69 (0.52) | CD69PTGDR2GSTA1GSTP1ELANE | |
| SCHEMBL18538272 | 0.74 | CD69 (0.52) | CD69PTGDR2GSTA1GSTP1ELANE | |
| SCHEMBL18538275 | 0.74 | CD69 (0.52) | CD69PTGDR2GSTA1GSTP1ELANE | |
| SCHEMBL5574627 | 0.70 | GSTA1 (0.44) | CD69GSTA1GSTP1 | |
| SCHEMBL217722 | 0.70 | LMNA (0.57) | PTGDR2 | |
| SCHEMBL5989809 | 0.69 | PTGDR2 (0.71) | PTGDR2TDP1 | |
| SCHEMBL5570767 | 0.69 | GSTA1 (0.45) | CD69GSTA1GSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027075-A1 | Compositions and methods for targeted drug delivery | UNIVERSITY OF CINCINNATI | 2007-02-01 | — | — | US | disclosed |
| WO-2005004795-A2 | COMPOSITIONS AND METHODS FOR TARGETED DRUG DELIVERY | UNIVERSITY OF CINCINNATI (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027075-A1 | Compositions and methods for targeted drug delivery | SLC47A1, SLC47A2, SLC46A1 | CD69 2441/4885PTGDR2 613/4885PGR 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.